Explore 3 Stock Ideas & Industry Insights Download Free Report

Accuray Incorporated

Healthcare US ARAY

0.3152USD
0.0024(0.77%)

Last update at 2026-06-23T14:52:00Z

Day Range

0.310.32
LowHigh

52 Week Range

0.332.10
LowHigh

Fundamentals

  • Previous Close 0.31
  • Market Cap50.02M
  • Volume188402
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.70000M
  • Revenue TTM436.97M
  • Revenue Per Share TTM3.89
  • Gross Profit TTM 121.69M
  • Diluted EPS TTM-0.31

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax 1.13M -11.82000M -6.78800M -2.00200M -4.55900M
Minority interest - - - - -
Net income -1.59100M -15.54500M -9.28000M -5.34700M -6.31100M
Selling general administrative 47.87M 50.07M 48.27M 44.39M 41.72M
Selling and marketing expenses 43.31M 42.62M 46.18M 49.66M 42.82M
Gross profit 146.97M 142.92M 153.96M 159.96M 159.51M
Reconciled depreciation 6.15M 5.91M 4.53M 5.51M 6.39M
Ebit 14.09M -0.19600M -2.14500M 2.63M 15.85M
Ebitda 20.24M 5.71M 2.38M 8.15M 22.23M
Depreciation and amortization 6.15M 5.91M 4.53M 5.51M 6.39M
Non operating income net other - - - -10.15000M -26.79400M
Operating income 7.84M 0.50M 2.38M 2.63M 15.85M
Other operating expenses 450.67M 446.05M 445.22M 421.76M 374.05M
Interest expense 12.95M 11.62M 10.63M 8.13M 16.89M
Tax provision 2.73M 3.73M 2.49M 3.35M 1.75M
Interest income 1.19M 1.23M - - -
Net interest income -11.76200M -11.62400M -10.63200M -8.12900M -16.89300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 2.73M 3.73M 2.49M 3.35M 1.75M
Total revenue 458.50M 446.55M 447.61M 429.91M 396.29M
Total operating expenses 139.13M 142.42M 151.58M 151.81M 137.27M
Cost of revenue 311.54M 303.63M 293.64M 269.95M 236.78M
Total other income expense net -6.70500M -12.32400M -9.17000M -4.63700M -20.40500M
Discontinued operations - - - - -
Net income from continuing ops -1.59100M -15.54500M -9.28000M -5.34700M -6.31100M
Net income applicable to common shares - - -9.28000M -5.34700M -6.31100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 470.24M 468.63M 479.21M 472.85M 480.10M
Intangible assets 0.01M 0.06M 0.21M 0.25M 0.43M
Earning assets - - - - -
Other current assets 21.16M 24.34M 27.61M 25.46M 25.11M
Total liab 389.07M 423.54M 425.56M 419.66M 411.26M
Total stockholder equity 81.17M 45.08M 53.66M 53.19M 68.84M
Deferred long term liab - - 9.24M 9.75M -
Other current liab 30.55M 47.00M 62.06M 59.73M 54.34M
Common stock 0.11M 0.10M 0.10M 0.09M 0.09M
Capital stock 0.11M 0.10M 0.10M 0.09M 0.09M
Retained earnings -519.27200M -517.68100M -502.13600M -492.52200M -488.02400M
Other liab - - 31.75M 14.20M 31.45M
Good will 57.80M 57.67M 57.68M 57.84M 57.96M
Other assets - - 21.38M 20.51M 18.14M
Cash 57.42M 68.57M 89.40M 88.74M 116.37M
Cash and equivalents - - - - -
Total current liabilities 192.58M 195.27M 198.64M 208.86M 192.36M
Current deferred revenue 94.50M 71.65M 92.96M 100.67M 106.60M
Net debt 118.96M 142.18M 115.63M 124.99M 83.04M
Short term debt 20.11M 20.19M 9.87M 17.13M 11.96M
Short long term debt 12.73M 7.76M 5.72M 8.56M 3.79M
Short long term debt total 176.38M 210.75M 205.04M 213.73M 199.41M
Other stockholder equity 602.16M 566.89M 555.28M 543.21M 554.68M
Property plant equipment - - 39.28M 29.48M 34.85M
Total current assets 317.46M 323.24M 338.03M 350.89M 352.77M
Long term investments 4.61M 9.83M 15.13M 13.88M 15.94M
Net tangible assets - - -11.73200M -4.90100M 10.45M
Short term investments - - - - 15.94M
Net receivables 97.87M 92.00M 74.78M 94.44M 85.36M
Long term debt 123.79M 164.40M 171.56M 171.91M 170.01M
Inventory 141.02M 138.32M 145.15M 142.25M 125.93M
Accounts payable 34.03M 50.02M 33.74M 31.34M 19.47M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.83700M -4.22200M 0.42M 2.41M 2.09M
Additional paid in capital - - - - -
Common stock total equity - - - 0.09M 0.09M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -492.52200M -488.02400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 27.82M 18.63M 21.38M 20.51M 18.14M
Deferred long term asset charges - - - - -
Non current assets total 152.77M 145.39M 141.18M 121.96M 127.33M
Capital lease obligations 39.86M 38.59M 27.75M 33.26M 25.61M
Long term debt total - - - 171.91M 170.01M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -8.52300M -3.60100M -12.68100M -4.71700M -0.07900M
Change to liabilities - - -4.43500M 18.36M -5.30300M
Total cashflows from investing activities -8.52300M - -12.68100M -4.71700M -2.39900M
Net borrowings 7.50M - -3.86500M -15.00000M -17.41200M
Total cash from financing activities -4.25200M -3.95100M -2.11200M -15.36900M -28.80500M
Change to operating activities - - -2.57500M 1.31M 6.18M
Net income -1.59100M -15.54500M -9.28000M -5.34700M -6.31100M
Change in cash -8.25800M -20.81000M 1.05M -28.04700M 8.29M
Begin period cash flow 70.39M 91.20M 90.15M 118.20M 109.91M
End period cash flow 62.13M 70.39M 91.20M 90.15M 118.20M
Total cash from operating activities 2.86M -11.90400M 15.54M -2.40000M 38.51M
Issuance of capital stock 1.63M 2.25M 2.20M 3.89M 3.03M
Depreciation 6.15M 5.91M 4.53M 5.51M 6.39M
Other cashflows from investing activities -4.25100M - - - -
Dividends paid - - 0.20M 0.26M 3.03M
Change to inventory -9.10900M -3.99800M -6.85500M -22.86100M 1.69M
Change to account receivables 13.36M -15.82600M 18.49M -12.51900M 5.24M
Sale purchase of stock - -0.11700M -0.19900M -0.25800M -14.08000M
Other cashflows from financing activities -13.37900M -0.19800M -0.44700M -0.25800M -0.34300M
Change to netincome - - 6.64M 15.92M 17.20M
Capital expenditures 8.52M 3.60M 12.68M 4.72M 2.32M
Change receivables - - - -12.51900M 5.24M
Cash flows other operating - - - -2.28000M -2.92500M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -22.48600M 7.31M
Change in working capital -18.20200M -21.91900M 4.62M -22.59900M 7.80M
Stock based compensation 10.20M 9.48M 10.05M 10.60M 9.33M
Other non cash items 6.15M 8.77M 5.16M 7.65M 21.42M
Free cash flow -5.66300M -15.50500M 2.86M -7.11700M 36.19M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARAY
Accuray Incorporated
0.0024 0.77% 0.32 - 94.34 0.11 1.03 0.43 26.28
ABT
Abbott Laboratories
2.41 2.74% 90.24 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation
5.38 1.77% 310.07 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC
1.33 1.68% 80.60 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp
0.77 1.74% 45.10 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

Profile

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Accuray Incorporated

1240 Deming Way, Madison, WI, United States, 53717-1954

Key Executives

Name Title Year Born
Ms. Suzanne Winter M.B.A. Pres, CEO & Director 1963
Mr. Ali Pervaiz Sr. VP & CFO NA
Mr. Michael Hoge Sr. VP of Global Operations NA
Mr. Jesse Chew Sr. VP, Gen. Counsel & Corp. Sec. 1981
Mr. Joshua H. Levine Consultant 1958
Mr. Franco N. Palomba VP, Chief Accounting Officer & Controller 1962
Dr. Jean-Philippe Pignol Sr. VP, Chief Medical & Technology Officer NA
Mr. GS Jha Global Chief Information Officer & Chief Information Security Officer NA
Mr. Patrick R. Spine Sr. VP & Chief Admin. Officer 1971
Ken Mobeck VP of Fin. & Investor Relations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions